Table 2. Laboratory and imaging studies at the time of initial care among patients who survived and died, infected by SARS-CoV-2.
| Characteristics | Total | Survivors | Deceased | p | |||
|---|---|---|---|---|---|---|---|
| n = 780 | % | n = 577 | % | n = 203 | % | ||
| Laboratory studies, median (IQR) | |||||||
| Blood count | |||||||
| Hemoglobin (g / dL) | 14.4 (13.1–15.5) | 14.6 (13.4–15.7) | 13.8 (12.2–14.8) | <0.001^ | |||
| Hematocrit (%) | 42.6 (38.7–46.3) | 43.2 (39.9–46.5) | 40.6 (37.0–45.3) | <0.001^ | |||
| Leukocytes (/ mm3) | 8.840 (6.280–11.710) | 8.155 (6.000–10.885) | 9.980 (8.000–14.125) | <0.001^ | |||
| Neutrophils (/ mm3) | 6.870 (4.450–9.630) | 6.235 (4.100–8.915) | 8.650 (6.087–11.925) | <0.001^ | |||
| Lymphocytes (/ mm3) | 1.000 (730–1.400) | 1.050 (792–1.500) | 844 (600–1.240) | <0.001^ | |||
| Platelets (mil / mm3) | 248.0 (190.0–309.0) | 254.0 (208.2–311.7) | 225.0 (171.0–277.0) | 0.001^ | |||
| Renal function | |||||||
| Creatinine (mg / dL) | 0.9 (0.7–1.1) | 0.9 (0.7–1.1) | 1.1 (0.8–1.6) | <0.001^ | |||
| Urea nitrogen (mg / dL) | 16.2 (12.5–23.7) | 15.3 (12.1–21.7) | 24.4 (17.0–36.9) | <0.001^ | |||
| Liver function | |||||||
| Total bilirubin (mg / dL) | 0.57 (0.39–0.92) | 0.52 (0.37–0.81) | 0.65 (0.44–0.90) | 0.008^ | |||
| Direct bilirubin (mg / dL) | 0.31 (0.20–0.49) | 0.26 (0.18–0.40) | 0.40 (0.25–0.56) | <0.001^ | |||
| Alanine aminotransferase (U / L) | 43.4 (26.1–61.0) | 38.8 (26.0–59.4) | 42.9 (27.0–68.0) | 0.377^ | |||
| Aspartate aminotransferase (U / L) | 43.0 (29.6–61.0) | 42.8 (28.2–61.0) | 54.9 (33.0–85.0) | 0.011^ | |||
| Lactic dehydrogenase (U / L) | 367.0 (284.0–489.0) | 359.0 (282.7–454.7) | 458.0 (347.0–611.0) | <0.001^ | |||
| Others | |||||||
| C-reactive protein (mg / L) | 130.5 (63.6–206.4) | 116.9 (49.4–186.1) | 166.5 (105.7–257.5) | <0.001^ | |||
| Ferritin (ng / mL) | 1010.5 (451.0–1906.7) | 899.0 (408.0–1657.4) | 1340.0 (555.3–2000.0) | 0.004^ | |||
| D-dimer (μg / mL) | 340.0 (20.0–648.0) | 299.5 (1.763–558.5) | 497.0 (283.0–1141.0) | <0.001^ | |||
| Troponin I (ng / mL) | 0.008 (0.004–0.019) | 0.007 (0.004–0.011) | 0.024 (0.008–0.055) | <0.001^ | |||
| Prothrombin time (sec) | 13.9 (10.6–15.3) | 12.9 (10.2–15.2) | 14.1 (10.9–15.4) | 0.023^ | |||
| Imaging studies | |||||||
| Chest x-ray | |||||||
| Abnormal findings | 392 | 50.3 | 290 | 50.3 | 102 | 50.2 | 0.997 |
| Infiltrate | 287 | 36.8 | 211 | 36.6 | 76 | 37.4 | 0.825 |
| Consolidation | 94 | 12.1 | 67 | 11.6 | 27 | 13.3 | 0.525 |
| Groud-glass opacity | 89 | 11.4 | 68 | 11.8 | 21 | 10.3 | 0.579 |
| Pleural effusion | 26 | 3.3 | 18 | 3.1 | 8 | 3.9 | 0.575 |
| Atelectasis | 23 | 2.9 | 18 | 3.1 | 5 | 2.5 | 0.634 |
| Air bronchogram | 10 | 1.3 | 7 | 1.2 | 3 | 1.5 | 0.726* |
| Chest Computed Tomography | |||||||
| Abnormal findings | 395 | 50.6 | 276 | 47.8 | 119 | 58.6 | 0.008 |
| Groud-glass opacity | 364 | 46.7 | 250 | 43.3 | 114 | 56.2 | 0.002 |
| Consolidation | 118 | 15.1 | 91 | 15.8 | 27 | 13.3 | 0.398 |
| Air bronchogram | 81 | 10.4 | 38 | 6.6 | 43 | 21.2 | <0.001 |
| Atelectasis | 45 | 5.8 | 31 | 5.4 | 14 | 6.9 | 0.423 |
| Lymphadenopathy | 38 | 4.9 | 29 | 5.0 | 9 | 4.4 | 0.736 |
| Bronchiectasis | 35 | 4.5 | 21 | 3.6 | 14 | 6.9 | 0.054 |
| Interlobular septal thickening | 28 | 3.6 | 12 | 2.1 | 16 | 7.9 | <0.001 |
| Pleural thickening | 27 | 3.5 | 19 | 3.3 | 8 | 3.9 | 0.664 |
IQR: Interquartile range;
* Fisher’s exact test;
^ Mann-Whitney U Test